Lindsey Gumbrell

3.5k total citations · 1 hit paper
24 papers, 2.7k citations indexed

About

Lindsey Gumbrell is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Lindsey Gumbrell has authored 24 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Lindsey Gumbrell's work include Cancer therapeutics and mechanisms (11 papers), Neuroendocrine Tumor Research Advances (4 papers) and Cancer Treatment and Pharmacology (4 papers). Lindsey Gumbrell is often cited by papers focused on Cancer therapeutics and mechanisms (11 papers), Neuroendocrine Tumor Research Advances (4 papers) and Cancer Treatment and Pharmacology (4 papers). Lindsey Gumbrell collaborates with scholars based in United Kingdom, Australia and New Zealand. Lindsey Gumbrell's co-authors include A. Hilary Calvert, David R. Newell, Martin Gore, Frances Boxall, Zahid H. Siddik, Ian Judson, Séamus O’Reilly, Matthew Burnell, E. Wiltshaw and Susan Galbraith and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Lindsey Gumbrell

24 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

1989 1.5k citations A. Hilary Calvert, David R. Newell et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Lindsey Gumbrell

Since Specialization

Citations

This map shows the geographic impact of Lindsey Gumbrell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsey Gumbrell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsey Gumbrell more than expected).

Fields of papers citing papers by Lindsey Gumbrell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsey Gumbrell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsey Gumbrell. The network helps show where Lindsey Gumbrell may publish in the future.

Co-authorship network of co-authors of Lindsey Gumbrell

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsey Gumbrell. A scholar is included among the top collaborators of Lindsey Gumbrell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsey Gumbrell. Lindsey Gumbrell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors 2009 ·Clinical Cancer Research ·Daniel Hochhauser, T Meyer, Victoria J. Spanswick, Jenny Wu, Peter H. Clingen, Paul M. Loadman, (unknown), Lindsey Gumbrell, Richard H. J. Beǵent, John A. Hartley, Duncan I. Jodrell	62
2	Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors 2006 ·Clinical Cancer Research ·Malcolm Ranson, Mark R. Middleton, John Bridgewater, Siow Ming Lee, Martin D. Dawson, (unknown), Gavin Halbert, S. Waller, Helen E. McGrath, Lindsey Gumbrell, R. Stanley McElhinney, Dorothy J. Donnelly, T. Brian H. McMurry, Geoffrey P. Margison	110
3	Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer 2005 ·Cancer Immunology Immunotherapy ·Ashita Waterston, Lindsey Gumbrell, Tomas Bratt, S. Waller, (unknown), (unknown), (unknown), Michael J. Campbell, Thomas Powles, Martin Highley, Mark Bower, S. Mouritsen, Marc Feldmann, R. Charles Coombes	23
4	5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study 2003 ·British Journal of Cancer ·Gordon Rustin, Christopher Bradley, Susan Galbraith, M.R.L. Stratford, Paul M. Loadman, S. Waller, (unknown), Lindsey Gumbrell, Lisa K. Folkes, Gavin Halbert	100
5	Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent 2003 ·British Journal of Cancer ·Michael B. Jameson, Paul Thompson, Bruce C. Baguley, B D Evans, V.J. Harvey, David Porter, (unknown), Maurice J. Small, (unknown), Lindsey Gumbrell, Gavin Halbert, P. Kestell	115
6	Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results 2003 ·Journal of Clinical Oncology ·Gordon Rustin, Susan Galbraith, Helén Anderson, Michael R.L. Stratford, Lisa K. Folkes, (unknown), Lindsey Gumbrell, Patricia M. Price	274
7	Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging 2002 ·Journal of Clinical Oncology ·Susan Galbraith, Gordon Rustin, Martin A. Lodge, N. Jane Taylor, James Stirling, Michael B. Jameson, Paul Thompson, David M. Hough, Lindsey Gumbrell, Anwar R. Padhani	121
8	Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer 1995 ·Cancer Chemotherapy and Pharmacology ·Michael Millward, David R. Newell, Kally Yuen, Jane Matthews, Kathryn Balmanno, (unknown), Lindsey Gumbrell, Michael Lind, Fiona Chapman, (unknown), (unknown), Brian M.J. Cantwell, A. Hilary Calvert	18
9	Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481) 1995 ·European Journal of Cancer ·Michael Millward, David R. Newell, (unknown), Linus N. Igwemezie, Kathryn Balmanno, (unknown), Lindsey Gumbrell, Michael Lind, (unknown), (unknown), (unknown), B.M.J. Cantwell, G. A. Taylor, (unknown), Benjamin Winograd, Sanjeev Kaul, (unknown), A H Calvert	12
10	The use of granuloctye colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer 1995 ·British Journal of Cancer ·(unknown), Lindsey Gumbrell, B.M.J. Cantwell, (unknown), (unknown), (unknown), (unknown), Edward McCann, (unknown), A H Calvert	7
11	Results of chemotherapy using ifosfamide with doxorubicin in advanced breast cancer 1994 ·Breast Cancer Research and Treatment ·Michael Millward, Michael Lind, Lindsey Gumbrell, Angela Byun Robinson, Thomas W. J. Lennard, Brian M.J. Cantwell	4
12	Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results 1993 ·Cancer Treatment Reviews ·A H Calvert, Michael Lind, (unknown), B.M.J. Cantwell, Lindsey Gumbrell, (unknown), (unknown), (unknown), Andrew Robinson, (unknown), Kathryn Balmanno, David R. Newell	30
13	Phase I trial of the anthrapyrazole CI-941: Prospective evaluation of a pharmacokinetically guided dose-escalation 1992 ·European Journal of Cancer ·(unknown), David R. Newell, Lindsey Gumbrell, A. Hilary Calvert, Marien Alet Graham, S.B. Kaye, (unknown)	17
14	Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. 1992 ·PubMed ·Marien Alet Graham, David R. Newell, (unknown), Lindsey Gumbrell, (unknown), A. Hilary Calvert	17
15	Phase I and Clinical Pharmacological Evaluation of Aphidicolin Glycinate 1991 ·JNCI Journal of the National Cancer Institute ·Cristiana Sessa, Massimo Zucchetti, Enrico Davoli, Raffaele Califano, Franco Cavalli, S. Frustaci, Lindsey Gumbrell, Aarón Sulkes, Benjamin Winograd, Maurizio D’Incalci	47
16	Carboplatin dosage: prospective evaluation of a simple formula based on renal function. breakdown → 1989 ·Journal of Clinical Oncology ·A. Hilary Calvert, David R. Newell, Lindsey Gumbrell, Séamus O’Reilly, Matthew Burnell, Frances Boxall, Zahid H. Siddik, Ian Judson, Martin Gore, E. Wiltshaw	1510
17	Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma 1989 ·Cancer Chemotherapy and Pharmacology ·David R. Newell, Rosalind A. Eeles, Lindsey Gumbrell, (unknown), A. Horwich, A. Hilary Calvert	38
18	Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). 1989 ·PubMed ·Ian Judson, A H Calvert, (unknown), G. Abel, Lindsey Gumbrell, Marien Alet Graham, B D Evans, D. E. V. Wilman, S. Ashley, F. Cairnduff	10
19	Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone 1988 ·Cancer Chemotherapy and Pharmacology ·P A Speth, Martin Gore, (unknown), David R. Newell, (unknown), (unknown), John A. Green, Lindsey Gumbrell, P. Linssen, Antonius A. Miller, Ian E. Smith, J. G. McVie, P.H.M. de Mulder, B.E. de Pauw, (unknown), G.W. Brown	5
20	Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin 1987 ·European Journal of Cancer and Clinical Oncology ·David R. Newell, Zahid H. Siddik, Lindsey Gumbrell, Frances Boxall, Martin Gore, Ian E. Smith, A. Hilary Calvert	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact